This company is currently in Phase 3 of a pre treatment autoimmune therapy drug multikine that is aiming to improve your chances of chemo therapy by 10%. Results are expected within the next 6-12 months. And it could really hit a home run on the back of Phase 3 results. In the short term I expect investors to start taking bets and a test of the 10 level once broken will ultimately lead to a target of 12. Lots of upside. LONG
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.